focus -WSS

focus

author：leisure time 2025-08-11 02:16:09 - browse：2226

In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp. — Scott Olson/Getty Images

WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.

The negotiated prices won’t take effect until 2026.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： How generative AI is inspiring dreams of a health data revolution

WSS

Amazon on where the company's health care bets are headed next

Achieving telehealth equity for people with hearing loss

Should insurance cover cosmetic surgery?

Covid hospitalizations on the rise, Humana says

Why some fertility treatments produce more boy babies

Weighted lottery helped low

Wikipedia

focus

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Trump surgeon general acknowledges mistakes during Covid

Virginia high school admissions case could be legal follow

'Make People Better': The CRISPR babies story you probably don't know

Medical records are filled with copy

House transparency, PBM reform bill gains bipartisan support

Duchenne breakthrough therapy leaves behind pioneering families

Listen: Biogen's potential pivot, & Illumina's next chapter

Tori Bowie and the unacceptable rates of Black maternal death

Bird flu makes raw milk dangerous to consume, mouse study finds

knowledge

Beyond aggravation: Constipation is an American epidemic

Why some fertility treatments produce more boy babies

NIH nominee Bertagnolli will get October confirmation hearing

NIH nominee Bertagnolli will get October confirmation hearing

Stem cell treatment guidelines are released by FDA

Why Novartis is changing the name of its research labs

Wikipedia

leisure time

explore

leisure time